How fast can a US site sign the clinical trial agreement?

For a sponsor, a site's activation can wait on the clinical trial agreement (CTA), not on patients. In my experience, for a practice's first study the slowest parts are usually the sponsor contract and budget negotiation, followed by regulatory and IRB paperwork and getting staff trained and delegated before the first patient. Enrollment itself is rarely the bottleneck when the practice already sees the right patients.

I'm Julio Martinez-Clark, CEO of Amavita Research, a cardiovascular clinical trial site in Miami. This article doesn't give a day count. It covers what speeds up the CTA: what a site can do, and what a sponsor or CRO can ask a site for.

The short answer

A CTA moves faster when there is less to negotiate and other start-up work isn't waiting on it. Four practices help:

1. Reusing an agreement the site has already negotiated with the same sponsor or CRO.
2. Budget lines the site has priced before the budget arrives, and rates agreed on earlier studies where they still fit.
3. The correct legal entity, signer and study locations, settled at the start.
4. IRB and other start-up work running alongside the contract instead of after it.

There's no single honest number for how long a CTA takes. It depends on the sponsor's template, how many changes the site needs, and how quickly each side's reviewers answer. What a site controls is how much it asks for and how fast it replies.

1. Start from an agreement you've already negotiated

When a site has already signed a CTA with the same sponsor or CRO, for example on an earlier study in the same program, the sponsor may offer a copy of that agreement for the new study, sometimes called a cloned agreement. The earlier terms give both sides a starting point, so the review can focus on what is new, subject to the sponsor's acceptance and the needs of the new protocol.

Two things decide whether that's actually faster:

• Say early whether you can accept it as written. A sponsor may offer the cloned agreement only on condition that the site accepts it as written. If the site can't, negotiation may have to start again from the sponsor's study-wide template. Ask early which applies.
• If you need changes, keep them few and explain each one. Send tracked changes with a margin comment giving the reason for each edit, and say plainly that you'd prefer the sponsor review them within the cloned agreement. A sponsor may agree to that. If its policy requires the study-wide template, offer to carry the same comments onto that version promptly, to limit the delay.

For a sponsor, offering a site the agreement it signed last time, and saying up front whether edits are allowed, can cut down the back-and-forth.

2. Price the standard lines before the budget arrives

The budget, often an exhibit to the CTA, can run on its own review track and may be escalated to the sponsor separately from the contract language. It can hold up signature on its own. A site can shorten this by pricing its standard lines before any budget arrives, in a rate card. Lines that come up often include:

• Start-up and IRB fees
• The coordinator per-visit fee
• Screen failures (a screen-fail ratio or a per-screen fee), unscheduled visits and phone visits
• Archiving and close-out fees

With a rate card, the site can answer a sponsor's budget line by line, cell by cell, on its first review, and give the reason for each counteroffer. Where a sponsor and site have agreed rates on an earlier study, those rates can be a starting point for the next one, adjusted for what the new protocol needs.

Ask whether the budget and the contract language can be reviewed at the same time. Often neither has to wait for the other to be finished.

3. The right legal entity, signer and study location

Small details can cost avoidable time. A CTA drawn up in the wrong legal name, or sent to someone who can't sign it, has to be corrected or reissued. Before the first draft is issued, the site should give the sponsor or CRO:

• The exact legal name of the contracting entity. This matters when a research company sits alongside a medical practice and the two have different names.
• Who signs for the site, whether the principal investigator also signs, and in what order.
• The site location or locations for the study. If only one address will be used, say so at the start.

The same facts apply to any confidentiality agreement (CDA) used for feasibility discussions. A site that keeps them on one page can send them in its first reply.

4. Run the IRB and other start-up work alongside the contract

If each step waits for the one before it, start-up takes as long as all of them added together. Some steps may not need to wait for the signed CTA:

• IRB preparation. Ask the sponsor, and the reviewing IRB, which preparation or submission steps may go ahead while the contract is in negotiation. Ask instead of assuming.
• Investigator documents. Ask which investigator and regulatory documents can be prepared during contract review.
• Items outside the core contract language. Where something isn't needed to sign, propose a way to handle it separately. For example, if the site's insurance policy is still being bound, the site can propose signing with interim insurance language and sending the certificate as soon as the broker issues it. The sponsor decides whether that works.

What a sponsor or CRO can ask a site for

To see whether a site will move quickly, ask:

• Have you signed a CTA with us or our CRO before, and could that agreement be reused?
• Do you have a rate card, and can you answer our budget line by line on the first review?
• What is your contracting legal entity, and who signs for the site?
• Can your IRB and regulatory work start before the contract is signed, if we allow it?

How we approach it at Amavita Research

Amavita Research is a contracted clinical research site. We are not a CRO. We price budgets from a written, versioned rate card, so standard lines don't have to be worked out study by study. Our CEO signs confidentiality agreements for the site. When we return a contract, our tracked changes carry the reason for each edit in a margin comment. If a sponsor offers a cloned agreement, we say clearly whether we can accept it as written and, if not, which edits we need and why.

To start, see our Sponsor FAQ or email julio@amavita.health.

FAQ

What slows down a clinical trial agreement at a US site?

Common causes are the number of changes each side needs, a budget on a separate review track, a wrong legal entity or signer, and steps that wait for the signed contract when they could run alongside it.

Does reusing a previously negotiated agreement speed up contracting?

It can, because the earlier terms give both sides a starting point. A sponsor may offer the reused agreement only if the site accepts it as written. If the site needs changes, it should keep them few, explain each one, and ask early whether edits are allowed.

Can the budget be negotiated at the same time as the contract?

Often, yes. The budget can run on its own review track. Ask whether both can move at once. A site with a rate card for standard lines can answer the budget line by line on its first review.

Can IRB submission start before the clinical trial agreement is signed?

Ask the sponsor and the reviewing IRB at the start which preparation or submission steps may go ahead during contract negotiation, instead of assuming.

Why does the legal entity matter on a CTA?

An agreement drawn up in the wrong legal name, or sent to someone who can't sign, has to be corrected or reissued. The site should give the exact contracting entity, its signers and the study locations before the first draft.